MedBulletinsAura Celeste
Pulmonology

Monthly pulmonology bulletin — November 9, 2026

🎧 Listen to this issueAudio newscast · 3:07 min

Period covered: October 10 to November 9, 2026. This issue includes only the items whose main figures could be checked against a primary document (an official release from the sponsor or from the regulator). The specific figures discussed here come from those releases; for OBERON and TITANIA, AstraZeneca states that the full results have already been published in the New England Journal of Medicine. The GOLD 2027 report had not been released when this issue closed.

Asthma and COPD

1. Tozorakimab (anti–IL-33) in COPD: symptom data from OBERON and TITANIA

[Meeting] [International; sponsor: AstraZeneca, United Kingdom]

On October 12, AstraZeneca released symptom data from the two phase 3 trials OBERON and TITANIA (2,306 patients randomized across both), presented at CHEST 2026, whose exacerbation results we covered last month. According to AstraZeneca, the full results of both trials were published in the New England Journal of Medicine; the symptom data below come from its release. Tozorakimab 300 mg every four weeks was compared with placebo for 52 weeks, on top of inhaled therapy. On the E-RS:COPD scale (0 to 40), the least squares mean change from baseline to week 52 was −2.31 (95% CI, −2.94 to −1.67) with tozorakimab versus −1.41 (95% CI, −2.05 to −0.77) with placebo in OBERON, and −1.92 (95% CI, −2.45 to −1.40) versus −0.84 (95% CI, −1.37 to −0.32) in TITANIA. At week 4, the difference versus placebo was −0.68 (95% CI, −1.40 to 0.04) in OBERON and −0.62 (95% CI, −1.22 to −0.03) in TITANIA. The company states that confidence intervals are not adjusted for multiplicity. The US license application is under priority review, with a decision expected in the first quarter of 2027, and it is also under review in the European Union, Japan, and China.

Why it matters: the difference versus placebo at week 52 is about one point on a 40-point scale (0.9 in OBERON and 1.1 in TITANIA), a small effect, with intervals not adjusted for multiplicity and from manufacturer-funded trials; no immediate impact on practice in the Dominican Republic.

Sources

Interstitial lung disease

2. Admilparant (LPA1 receptor antagonist) meets the primary endpoint in idiopathic pulmonary fibrosis at the 60 mg dose

[Industry] [International; sponsor: Bristol Myers Squibb, United States]

On October 12, Bristol Myers Squibb announced topline results from ALOFT-IPF (NCT06003426), a phase 3, multicenter, randomized, double-blind, placebo-controlled trial in about 1,255 adults aged 40 or older with idiopathic pulmonary fibrosis, randomized 1:1:1 to admilparant 60 mg twice daily, 120 mg twice daily, or placebo for at least 52 weeks. The 60 mg dose produced a statistically significant improvement in the primary endpoint, absolute change in forced vital capacity from baseline to week 52; the 120 mg dose slowed decline but did not reach significance. The company describes both doses as well tolerated, with low discontinuations due to adverse events, similar to placebo. The release gives no effect size, intervals, P values, or secondary endpoints. ALOFT-PPF (progressive pulmonary fibrosis, about 1,057 adults aged 21 or older, with or without stable background antifibrotic therapy; NCT06025578) is fully enrolled, with topline results expected in early 2027.

Why it matters: this would be a third oral mechanism against fibrosis, but the lack of a significant effect at the higher dose, the absence of figures, and no data on how many patients were on background antifibrotics mean we must await the full presentation before judging its place.

Sources

Cross-cutting

3. FDA grants accelerated approval to Voceryq, the first plasmid DNA immunotherapy, for recurrent respiratory papillomatosis

[FDA regulatory] [United States]

On October 30, the FDA granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd, from Inovio Pharmaceuticals), given by intramuscular injection with the CELLECTRA 5PSP electroporation device, for the treatment of adults with recurrent respiratory papillomatosis. The approval is based on an intermediate endpoint, the frequency of surgical procedures. The open-label, multicenter trial enrolled 32 adults with two or more surgeries to remove laryngotracheal papillomas in the previous 12 months; efficacy was assessed in 26 patients with at least three baseline surgeries, and 27% (7 of 26) needed no surgical intervention in the first year after treatment. The company must conduct post-approval trials to verify and describe clinical benefit.

Why it matters: it is a new option for a highly disabling airway disease, of interest to interventional pulmonologists, but the evidence comes from a small trial without a control group, with no surgeries in only a quarter of patients, and the product is not registered in the Dominican Republic.

Sources

Upcoming meetings and dates

  • GOLD 2027 COPD report: announced as imminent (preview published November 6). We will review it once published.

https://www.hcplive.com/view/2027-gold-report-update-preview-changes-copd-treatment-biologics

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.